Thomasian Harry Jr. sold $183K of PGEN

Thomasian Harry Jr. (Chief Financial Officer) sold 41,884 shares of PRECIGEN, INC. (PGEN) at $4.36 ($0.18M total) on 2026-05-28.

Original reporting
SEC EDGAR · Thomasian Harry Jr.
Published Jun 1, 2026, 8:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PGEN
Neutral
medium confidence
Mentioned
$PGEN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

This provides a datapoint on insider behavior (open-market sale) but does not introduce new company fundamentals like trial results, guidance, financing, or contracts.

02

Market read

Traders may monitor for follow-through selling pressure, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

Insider sales often occur for tax/financial planning; without context on total compensation, prior sales, or remaining holdings, signal strength is weak.

Relevance 6/10Novelty 6/10Timing: after SEC filing (filed 2026-06-01) for a sale executed 2026-05-28

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure by Precigen’s CFO.

Company-level read

Ticker impact

$PGENNeutralMedium confidence
Context

SEC Form 4 shows CFO Harry Jr. sold 41,884 shares of Precigen at $4.36/share, disclosing direct insider selling activity.

Expected impact

Low near-term impact; any move is likely sentiment-driven and limited unless accompanied by other news.

Evidence & confidence

The filing is an ownership-change disclosure with no new operating/financial information; also explicitly notes no 10b5-1 plan, which can raise attention but still lacks a direct causal catalyst.

Market effects

Limited read-across to biotech/clinical-stage sentiment; insider selling is company-specific and typically not sector-wide.

None indicated; US-listed microcap/small-cap style flow effects only.

None indicated.

Counterpoint

The sale could be routine liquidity/portfolio rebalancing; absence of a 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • PRECIGEN, INC.

    Company whose CFO reported an open-market sale of shares via SEC Form 4.

  • Thomasian Harry Jr.

    Precigen CFO who sold 41,884 shares at $4.36/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PGENHighAI 9/10

PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings

Precigen (PGEN) shares dropped 20% premarket after Inovio's (INO) FDA-approved rival treatment, Voceryq, challenged Papzimeos. PGEN reported $53.1M Q2 revenue. Retail investors remain optimistic about a potential buyout. Voceryq expects shipments in 60 days, with full deployment in early 2027. Clinical trials showed higher surgery-free rates for Papzimeos (51%) vs. Voceryq (27%).

$INOHighAI 9/10

FDA Grants Accelerated Approval to Inovio's DNA Immunotherapy Voceryq; Precigen Shares Plunge 27% After Hours

FDA granted accelerated approval to Inovio's (INO) DNA immunotherapy Voceryq for recurrent respiratory papillomatosis. Inovio shares surged 300% after hours, while Precigen's (PGEN) shares dropped 27% on market competition concerns. Voceryq is the first plasmid DNA-based immunotherapy approved in the U.S. and the second treatment for the disease.

$PGENMedAI 8/10

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.

$PGENHighAI 8/10

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Precigen, Inc. (PGEN) announced that the FDA granted platform technology designation to its AdenoVerse® immunotherapeutic platform, used in its commercial product PAPZIMEOS®. This designation may accelerate the development of future therapies by leveraging existing data and reducing duplicative work. The company's CEO highlighted the potential benefits for its clinical portfolio, including PRGN-2009 for HPV-associated cancers.

$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.